Analysts at StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Stock Down 1.5 %
Shares of NASDAQ:RDHL opened at $2.56 on Thursday. RedHill Biopharma has a fifty-two week low of $2.47 and a fifty-two week high of $20.28. The firm has a 50-day simple moving average of $5.13 and a 200 day simple moving average of $7.08.
Institutional Investors Weigh In On RedHill Biopharma
A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC acquired a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned about 0.40% of RedHill Biopharma as of its most recent SEC filing. 7.20% of the stock is currently owned by hedge funds and other institutional investors.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Further Reading
- Five stocks we like better than RedHill Biopharma
- 3 Dividend Kings To Consider
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Short a Stock in 5 Easy Steps
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
